...
首页> 外文期刊>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics >Perioperative use of 0.12% chlorhexidine gluconate for the prevention of alveolar osteitis: efficacy and risk factor analysis.
【24h】

Perioperative use of 0.12% chlorhexidine gluconate for the prevention of alveolar osteitis: efficacy and risk factor analysis.

机译:围手术期使用0.12%葡萄糖酸氯己定预防肺泡性骨炎的疗效和危险因素分析。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVES: The purposes of this study were to evaluate the use of 0.12% chlorhexidine gluconate as a prophylactic therapy for the prevention of alveolar osteitis and to further examine subject-based risk factors associated with alveolar osteitis. STUDY DESIGN: The trial was a randomized, double-blind, placebo-controlled, parallel-group study conducted among 279 subjects, each of whom required oral surgery for the removal of a minimum of one impacted mandibular third molar. Subjects were instructed to rinse twice daily with 15 ml of chlorhexidine or placebo mouthrinse for 30 seconds for 1 week before and 1 week after the surgical extractions. This regimen included a supervised presurgical rinse. Alveolar osteitis diagnosis was based on the subjective finding of increasing postoperative pain at the surgical site that was not relieved with mild analgesics, supported by clinical evidence of one or more of the following: loss of blood clot, necrosis of blood clot, and exposed alveolar bone. RESULTS: In comparison with use of the placebo mouthrinse, prophylactic use of the chlorhexidine mouthrinse resulted in statistically significant (p < 0.05) reductions in the incidence of alveolar osteitis. With chlorhexidine therapy, the subject- and extraction-based incidences of alveolar osteitis in the evaluable subset (271 subjects) were reduced, relative to placebo, by 38% and 44%, respectively. The corresponding odds ratios that describe the increased odds of experiencing alveolar osteitis in the placebo group were 1.87 and 2.05 for subject- and extraction-based analyses, respectively. In comparison with nonuse of oral contraceptives, the use of oral contraceptives in female subjects was related to a statistically significant increase in the incidence of alveolar osteitis (odds ratio = 1.92, p = 0.035). Relative to male subjects, the observed incidence of alveolar osteitis for female subjects not using oral contraceptives was not statistically significant (odds ratio = 1.18, p = 0.64). Smoking did not increase the incidence of alveolar osteitis relative to not smoking (odds ratio = 1.20, p = 0.33). CONCLUSIONS: These data confirm that the prophylactic use of 0.12% chlorhexidine gluconate mouthrinse results in a significant reduction in the incidence of alveolar osteitis after the extraction of impacted mandibular third molars. In addition, oral contraceptive use in females was confirmed to be a risk factor for the development of alveolar osteitis.
机译:目的:本研究的目的是评估0.12%葡萄糖酸氯己定作为预防性治疗肺泡性骨炎的预防方法,并进一步检查与肺泡性骨炎相关的受试者危险因素。研究设计:该试验是对279名受试者进行的一项随机,双盲,安慰剂对照,平行组研究,每名受试者都需要进行口腔手术,以去除至少一个受影响的下颌第三磨牙。指示受试者在手术提取前1周和术后1周每天用15 ml洗必泰或安慰剂漱口水冲洗两次,持续30秒。该方案包括有监督的手术前冲洗。肺泡性骨炎的诊断基于以下主观发现:手术部位术后疼痛增加,而轻度镇痛药无法缓解,并得到以下一项或多项临床证据的支持:血凝块丢失,血凝块坏死和肺泡暴露骨。结果:与使用安慰剂漱口水相比,预防性使用洗必泰漱口水可导致牙槽骨炎的发生率具有统计学显着性降低(p <0.05)。相对于安慰剂,使用洗必泰治疗,可评估亚组(271名受试者)中基于受试者和提取物的肺泡性骨炎的发生率分别降低了38%和44%。对于基于受试者和基于提取物的分析,描述安慰剂组中发生肺泡性骨炎的几率增加的相应几率分别为1.87和2.05。与不使用口服避孕药相比,女性受试者使用口服避孕药与肺泡性骨炎发生率的统计显着增加有关(比值比= 1.92,p = 0.035)。相对于男性受试者,未使用口服避孕药的女性受试者的肺泡性骨炎的发生率无统计学意义(比值比= 1.18,p = 0.64)。相对于不吸烟,吸烟并没有增加肺泡性骨炎的发生率(优势比= 1.20,p = 0.33)。结论:这些数据证实,预防性使用0.12%葡萄糖酸洗必太漱口水可导致下颌第三磨牙摘除后肺泡性骨炎的发生率显着降低。此外,已证实女性口服避孕药是肺泡性骨炎发展的危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号